| 1.38 -0.01 (-0.72%) | 01-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.68 | 1-year : | 1.79 |
| Resists | First : | 1.44 | Second : | 1.53 |
| Pivot price | 1.39  |
|||
| Supports | First : | 1.28 | Second : | 1.06 |
| MAs | MA(5) : | 1.37 |
MA(20) : | 1.38 |
| MA(100) : | 1.28 |
MA(250) : | 1.07 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 39.8 |
D(3) : | 35.9 |
| RSI | RSI(14): 45 |
|||
| 52-week | High : | 3.86 | Low : | 0.38 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RANI ] has closed above bottom band by 40.4%. Bollinger Bands are 82.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 31 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.39 - 1.4 | 1.4 - 1.41 |
| Low: | 1.32 - 1.33 | 1.33 - 1.34 |
| Close: | 1.36 - 1.38 | 1.38 - 1.4 |
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Fri, 23 Jan 2026
Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI), Ardelyx (ARDX) and AxoGen (AXGN) - The Globe and Mail
Thu, 08 Jan 2026
Rani Therapeutics begins phase 1 trial of oral obesity treatment - Investing.com
Thu, 08 Jan 2026
Rani Therapeutics Initiates Phase 1 Study of RT-114 - GlobeNewswire
Sat, 03 Jan 2026
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Fri, 02 Jan 2026
Rani Therapeutics finalizes governance and capital structure changes - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 98 (M) |
| Held by Insiders | 7.495e+007 (%) |
| Held by Institutions | 5.7 (%) |
| Shares Short | 10,600 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -4.004e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 418.2 % |
| Return on Equity (ttm) | -95.6 % |
| Qtrly Rev. Growth | 1.2e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 2.72727e+006 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.8 |
| Dividend | 0 |
| Forward Dividend | 1.389e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|